Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OM-85 for prevention of lower respiratory tract infections and wheeze in moderate-late preterm infants
NL-OMON55914Phase 3Recruiting
- Sponsor
- Franciscus Gasthuis & Vlietland
- Start
- Mar 2022
- Modality
- Whole Cell Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in pulmonary infection comparing OM-85 with Placebo (2 arms). Primary endpoints: Doctor diagnosed lower respiratory tract infection and wheezing episodes in the first year of life and Time to first lower respiratory episode in the second year of life. Started Mar 2022; status: recruiting.
02
Drugs
OM-85
03
Conditions
pulmonary infection
Beyond the preview
Go deeper on NL-OMON55914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55914.